Lingzhi Yan

7PUBLICATIONS
15CO-AUTHORS
Predictive and prognostic markersMedical mycologyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 18, 2025
Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.

Hongying You, Weiqin Yao, Lingzhi Yan

|Oct 11, 2022
Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.

Qian Wang, Wen-Zhi Cai, Qin-Rong Wang

|Aug 15, 2022
Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.

Yingying Zhai, Jingjing Shang, Weiqin Yao

|Feb 03, 2022
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.

Xiaolan Shi, Lingzhi Yan, Jingjing Shang

|Dec 28, 2020
Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.

Lingzhi Yan, Su Qu, Jingjing Shang

|Feb 05, 2020
High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype.

Xiaoyu Xu, Zhao Zeng, Li Huo

Pageof 2

Frequent Collaborators

2 joint publications

Yue Han

2 joint publications

Chengcheng Fu

1 joint publications

Qian Wang

1 joint publications

Ling Zhang